Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia von Reichard, Holly A, Schiffer, Hans H, Monenschein, Holger, Atienza, Josephine M, Corbett, Gerard, Skaggs, Alton W, Collia, Deanna R, Ray, William J, Serrats, Jordi, Bliesath, Joshua, Kaushal, Nidhi, Lam, Betty P, Amador-Arjona, Alejandro, Rahbaek, Lisa, McConn, Donavon J, Mulligan, Victoria J, Brice, Nicola, Gaskin, Philip L. R, Cilia, Jackie, Hitchcock, Stephen

Volltext

Lysosomes contribute to anomalous pharmacokinetic behavior of melanocortin-4 receptor agonists von YUPING GONG, ZHIYANG ZHAO, MCCONN, Donavon J, BEAUDET, Beth, TALLMAN, Melanie, SPEAKE, Jason D, IGNAR, Diane M, KRISE, Jeffrey P

Volltext

Dose-Related Reduction in Bupropion Plasma Concentrations by Ritonavir von Park, Joohyun, Vousden, Marika, Brittain, Claire, McConn, Donavon J., Iavarone, Laura, Ascher, John, Sutherland, Suzanne M., Muir, Keith T.

Volltext

Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With Cirrhosis von McConn, DJ, Lin, YS, Mathisen, TL, Blough, DK, Xu, Y, Hashizume, T, Taylor, SL, Thummel, KE, Shuhart, MC

Volltext

Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazol-3-one, by Fra... von Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Volltext

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-triazol-3-one, by... von Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Volltext

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazo... von Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Volltext

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-tr... von Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Volltext

2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV von Haffner, Curt D., McDougald, Darryl L., Reister, Steven M., Thompson, Brian D., Conlee, Christopher, Fang, Jing, Bass, Jonathan, Lenhard, James M., Croom, Dallas, Secosky-Chang, Melissa B., Tomaszek, Thaddeus, McConn, Donavon, Wells-Knecht, Kevin, Johnson, Paul R.

Volltext